Phaseline

Targets › SLITRK6

SLITRK6 (SLIT and NTRK-like protein 6): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Oct 2027.

Regulator of neurite outgrowth required for normal hearing and vision. (UniProt, Q9H5Y7)

Open in Phaseline: the race on SLITRK6, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Cancer Institute (NCI)ADCT-701
anti-SLITRK6 antibody-drug conjugate
SLITRK6Phase 1Neuroendocrine CarcinomasOct 2027

Conditions

Neuroendocrine Carcinomas (1)

Modalities

small molecule (1)

Companies

National Cancer Institute (NCI) (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.